Loading organizations...
Key people at adMare BioInnovations.
adMare BioInnovations develops and scales life sciences companies, applying scientific and commercial expertise, specialized R&D infrastructure, and seed capital. It functions as a drug discovery hub, supporting early-stage research progression into market-ready products. The organization provides critical resources and strategic guidance, transforming scientific breakthroughs into commercial successes benefiting patients.
Formed in 2019 from the merger of the Centre for Drug Research and Development (CDRD) and the NEOMED Institute, adMare BioInnovations optimized Canada’s life sciences commercialization landscape. Gordon C. McCauley, as President and CEO, guided the new pan-Canadian entity during its inception. This strategic consolidation addressed a key need within the national ecosystem.
adMare primarily serves emerging and established entities within the life sciences industry, including biotech startups and research institutions seeking commercialization. Its core mission cultivates a robust Canadian life sciences ecosystem, fostering innovation and growth nationwide. The organization envisions identifying, developing, and launching impactful health innovations, enhancing Canada’s global leadership.
Key people at adMare BioInnovations.
adMare BioInnovations has 5 tracked investments across 4 companies. The latest tracked deal is $2.4B Series B in Kainova Therapeutics in February 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 10, 2026 | Kainova Therapeutics | $2.4B Series B | Investissement Québec | 3B Future Health Fund, CTI Life Sciences Fund, Panacea Venture, Schroders Capital, Seido Capital, Seventure Partners, Turenne Capital, Viva BioInnovator |
| Jan 9, 2026 | Find Therapeutics | $7.2M Series A Extension | — | CTI Life Sciences Fund, Investissement Québec |
| Apr 1, 2023 | Abdera Therapeutics | $140.0M Series B | Nancy Harrison, Joel Drewry | VenBio Partners, AbCellera, Northview Ventures |
| Oct 1, 2022 | Inversago Pharma | $69.0M Series C | NEW Enterprise Associates | Accel, Advent Life Sciences, AmorChem, Atlas Venture, Benchmark, Bond, Forbion, Longwood Fund, Matrix, ED Mathers, Novartis Venture Fund, Soffinova Partners, Sofinnova Investments, Amgen Ventures, Genesys Capital, JDRF |
| Sep 1, 2020 | Inversago Pharma | $35.0M Series B | Forbion | AmorChem, Atlas Venture, Longwood Fund, ED Mathers, Anges Québec Capital, Genesys, JDRF T1D Fund |
